Document is current
Any future updates will be listed below
-
Authors
Lashkari, Reyhaneh
Dahl, Cecilie
Borgen, Tove T.
Bjørnerem, Åshild
Gjertsen, Jan-Erik
Wisløff, Torbjørn
Stutzer, Jens-Meinhard
Figved, Wender
Hansen, Ann Kristin
Solberg, Lene B.
Frihagen, Frede
Heen, Espen
Omsland, Tone K.
-
Funding
Funding for this research was provided by:
University of Oslo
- License Information
-
More Information
Article History
Received: 28 November 2024
Accepted: 31 May 2025
First Online: 23 June 2025
Declarations
:
: RL, TKO, CD, TW, JST, WF, AKH, ÅB, and EH declare that they have no conflict of interest; TTB reports speaker fees from UCB, Amgen, Roche Diagnostics, and Pharma Prim and participation in the advisory board for UCB; JEG reports speaker fees from Ortomedic (Norwegian distributor for DePuy Synthes), Smith & Nephew, LINK Norway, and Heraeus Medical; LBS reports speaker fees from Eli Lilly, UCB, and Amgen; FF reports speaker fees from Amgen and UCB. Data from the Norwegian Patient Registry were used in this publication. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Norwegian Patient Registry is intended or should be inferred.
